June 2013
Volume 54, Issue 15
ARVO Annual Meeting Abstract  |   June 2013
Response of uveitis-related retinal vasculitis to therapy with systemic infliximab
Author Affiliations & Notes
  • Pramod Sharma
    Uveitis, Massachusetts Eye Research and Surgery Institution, Cambridge, MA
    Ophthalmology, VSS Medical College, Burla, Sambalpur, India
  • Gueorgui Markov
    Uveitis, Massachusetts Eye Research and Surgery Institution, Cambridge, MA
    Ophthalmology, University Eye Hospital ''Professor Pashev'', Sofia, Bulgaria
  • C. Stephen Foster
    Uveitis, Massachusetts Eye Research and Surgery Institution, Cambridge, MA
    Harvard Medical School, Boston, MA
  • Footnotes
    Commercial Relationships Pramod Sharma, None; Gueorgui Markov, None; C. Stephen Foster, Abbott Medical Optics (C), Abbott Medical Optics (F), Alcon Laboratories, Inc. (C), Alcon Laboratories, Inc. (F), Allergan, Inc. (C), Allergan, Inc. (F), Eyegate Pharmaceuticals, Inc. (I), Eyegate Pharmaceuticals, Inc. (F), IOP Opthalmics (C), Ista Pharmaceuticals (C), Lux Biosciences, Inc. (C), Lux Biosciences, Inc. (F), Novartis Pharmaceuticals Corporation (C), Novartis Pharmaceuticals Corporation (F), XOMA Ltd (C)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 2052. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Pramod Sharma, Gueorgui Markov, C. Stephen Foster; Response of uveitis-related retinal vasculitis to therapy with systemic infliximab. Invest. Ophthalmol. Vis. Sci. 2013;54(15):2052.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: To assess the effect of infliximab on inducing remission in patients with uveitis associated with retinal vasculitis.

Methods: Retrospective case series study of the clinical records of 48 consecutive patients, who received infliximab for uveitis with associated vasculitis at MERSI, between 7/2005 and 7/2012, for at least 12 months. Effect was assessed on the basis of findings from fluorescein angiography and optical coherence tomography.

Results: From all 48 patients (100%) with uveitis and retinal vasculitis, 12 (25%) were male, and 36 (75%) - female. Age varied from 10 to 70 years. A total of 91 eyes were affected. Follow-up was from 12 to 78 months. Anterior uvetitis was diagnosed in 3(6.25%), intermediate - in 7 (14.58%), posterior - in 11(22.91%), panuveitis - in 12(25%),scleritis in 1(2.08). In addition we had birdshot retinochoroidopathy in 7 cases (14.58%), Behcet’s disease in 6(12.5%), and sympathetic ophthalmia in 1 (2.08%). Average dose of Infliximab was 5mg/kg. Sustained control of inflammation was achieved in 40 (83.3%) out of 48 patients. Average time for control of vasculitis was from 3 to 6 months In 2 cases infliximab was discontinued due to rise of liver enzymes. One (2.08%) case improved after rescue therapy with cyclophosphamide. One (2.08%) developed optic nerve demyelination. 2 (4.1%) cases developed lupus-like rash. One patient (2.08%) improved after pars plana vitrectomy and/or periocular or intravitreal corticosteroid injections. Relapses occurred due to temporary discontinuation of infliximab secondary to flu or pneumonia in one patient (2.08%). 1 (2.08%) had a relapse after stretching of infusion interval but subsequently improved on decreasing the interval. One patient (2.08%) showed good response but had to stop due to insurance issues. 1 (2.08) achieved remission without needing further therapy.

Conclusions: Uveitis associated with retinal vasculitis is a sight-threatening condition necessitating immunomodulatory therapy in a large percentage of patients. Infliximab appears to be a useful therapeutic agent which can lead to a sustained control of inflammation over a long period of follow-up.

Keywords: 555 immunomodulation/immunoregulation • 746 uveitis-clinical/animal model • 688 retina  

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.